Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Endocrinología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 4
ClinicalTrials.gov
A 24 Week Randomised, Open Label, 3 Parallel-group Comparison of Once and Twice Daily Biphasic Insulin Aspart (BIAsp) 30 Plus Sitagliptin and Twice Daily BIAsp 30, All in Combination With Metformin in Insulin naïve Type 2 Diabetic Subjects Inadequately Controlled on Sitagliptin and Metformin
INTERVENTIONAL
Inicio: 1 de jun de 2012
ID: NCT01519674
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis
INTERVENTIONAL
Inicio: 20 de nov de 2018
ID: NCT03710291
Completado
ClinicalTrials.gov
Hemoglobin A1c and Immediate Postsurgical Complications Diabetes Type 2 (HbA1c)
OBSERVATIONAL
Inicio: 1 de jul de 2011
ID: NCT01403961
Completado
ClinicalTrials.gov
Use of a Flexible Catheter for the Administration of Subcutaneous Insulin in Diabetic Ketoacidosis
INTERVENTIONAL
Inicio: 11 de dic de 2016
ID: NCT03182569
Completado
ClinicalTrials.gov
Optimizing Diagnostic Accuracy of Fine Needle Aspiration Biopsy Calcitonin Measurements in Detecting Medullary Thyroid Carcinoma
OBSERVATIONAL
Inicio: 1 de mar de 2018
ID: NCT06067594
Completado
Fase 3
ClinicalTrials.gov
A Trial Comparing Efficacy and Safety of NN1250 With Sitagliptin in Insulin Naive Subjects With Type 2 Diabetes (BEGIN™ : EARLY)
INTERVENTIONAL
Inicio: 1 de ene de 2010
ID: NCT01046110
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
INTERVENTIONAL
Inicio: 18 de ene de 2024
ID: NCT06018337
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
INTERVENTIONAL
Inicio: 1 de jul de 2020
ID: NCT04450394
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
INTERVENTIONAL
Inicio: 5 de abr de 2018
ID: NCT03495102
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
INTERVENTIONAL
Inicio: 20 de sept de 2024
ID: NCT06603571
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care.
INTERVENTIONAL
Inicio: 17 de sept de 2015
ID: NCT02545049
Completado
Fase 3
ClinicalTrials.gov
Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction
INTERVENTIONAL
Inicio: 16 de mar de 2021
ID: NCT04788511
Retirado
Fase 2
ClinicalTrials.gov
A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
INTERVENTIONAL
Inicio: 23 de may de 2025
ID: NCT06901349
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2, Parallel-Group, Double-Blind 4-arm Study to Investigate the Effects of Treatment With LY3549492 Tablets Compared With Placebo in an Obese or Overweight Population With Type-2 Diabetes (T2D)
INTERVENTIONAL
Inicio: 19 de jun de 2025
ID: NCT07030868
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
INTERVENTIONAL
Inicio: 27 de ago de 2021
ID: NCT04961996
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)
INTERVENTIONAL
Inicio: 6 de feb de 2017
ID: NCT02987543
Reclutando
Fase 3
ClinicalTrials.gov
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
INTERVENTIONAL
Inicio: 30 de abr de 2025
ID: NCT06948435
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
INTERVENTIONAL
Inicio: 19 de oct de 2020
ID: NCT04446117
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
INTERVENTIONAL
Inicio: 16 de nov de 2023
ID: NCT06016738
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)
INTERVENTIONAL
Inicio: 1 de ene de 2013
ID: NCT01769378
Anterior
1
...
14
15
16
...
434
Siguiente
Filtros